TL-77   Click here for help

GtoPdb Ligand ID: 7834

Compound class: Synthetic organic
Comment: The discovery of the TL-77, is described in [2] (and also as compound 9a in [1]). This compound is reported to have improved oral bioavailability compared to rigosertib, and represents a lead anti-mitotic, anti-cancer agent with potential for further development.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 146.88
Molecular weight 472.1
XLogP 1.97
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(OC)c(c(c1)OC)C=CS(=O)(=O)Cc1cnc(c(c1)NS(=O)(=O)C)OC
Isomeric SMILES COc1cc(OC)c(c(c1)OC)/C=C/S(=O)(=O)Cc1cnc(c(c1)NS(=O)(=O)C)OC
InChI InChI=1S/C19H24N2O8S2/c1-26-14-9-17(27-2)15(18(10-14)28-3)6-7-31(24,25)12-13-8-16(21-30(5,22)23)19(29-4)20-11-13/h6-11,21H,12H2,1-5H3/b7-6+
InChI Key HEBBDGMHRHUJRY-VOTSOKGWSA-N
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Treatment of cells with TL-77 causes a dose-dependent reduction of phosphorylated Cdc25c, which is known substrate of both polo-like kinase 1(PLK1) and CHK1/2. This indicates that TL-77 may act as an inhibitor of PLK1 and/or CHK1/2 (Abstract 3406: Evaluation of (E)-Styrylsulfonyl methylpyridine: A novel kinase inhibitor targeting mitotic pathways, AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC).